Press Release

A USD 2 Billion Saudi Arabia Diabetes Drug Market to Flourish at a CAGR of Around 9% During 2025-30

The Saudi Arabia Diabetes Drug Market size was valued at around USD 2 billion in 2024 and is projected to reach USD 3.4 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 9% during the forecast period (2025-30), cites MarkNtel Advisors in the recent research report. The market growth is attributed to the high prevalence of diabetes in Saudi Arabia due to obesity, dormant lifestyles, and dietary habits. This creates a demand for diabetes treatments and medicines including various types of drugs like; Victoza, Byetta, Metformin, Invokana, and others. Various government initiatives like the National Program for Educating on Diabetes, Training programs, and others are emphasizing improving healthcare access, diabetes screening, and prevention programs. Market expansion is also aided by rising public and private sector investments in healthcare infrastructure such as; reasonably priced insulin options and digital health platforms.

Furthermore, the demand for advanced therapy options in Saudi Arabia is driving the market ahead. GLP-1 receptor agonists, basal insulins, and SGLT-2 inhibitors are the most used medicines in the market due to their effective control over sugar levels and reduced risks associated with cardiovascular diseases. Also, in the price-sensitive healthcare market, cost-effective biosimilars are becoming more popular, especially for the long-term management of diabetes making them a significant market trend. Furthermore, some innovations like digital diabetes care platforms and continuous glucose monitoring (CGM) devices are transforming patient outcomes and treatment adherence leading to market growth.

Some challenges can hamper the market growth. Despite the provision of subsidies, innovative therapies might remain unaffordable to poor groups in many regions of Saudi Arabia because of their high prices. Also, the rural population often has low awareness about the complications and management of diabetes, creating challenges for market growth, further estates the research report, “Saudi Arabia Diabetes Drug Market Analysis, 2025.”

Saudi Arabia Diabetes Drug Market Segmentation Analysis

Basal Insulin Segment Captures the Largest Market Share

Based on the insulins, the market is further bifurcated into Basal, Bolous, Traditional Insulins, and Biosimilar Insulins. Within the insulin segment, basal insulins or long-acting insulins have maintained a higher market share in Saudi Arabia, approximately about 43.75 %. Products like Lantus, Levemir, and Tresiba fall within this category, offering steady blood glucose control for an extended period. Widespread use of these drugs in Saudi Arabian clinical settings and the effectiveness in controlling Type 1 and Type 2 diabetes explain the increase. Such basal insulin need can be further augmented by the fact that a large majority percentage of Saudi Arabia's diabetics have Type 2 diabetes that often progresses to a point where long-acting insulin becomes a requirement to be part of treatment. Additionally, the Saudi government is funding diabetes education and care that promotes early diagnosis and treatment compliance which aligns with the use of basal insulin.

Central Saudi Arabia Leading the Diabetes Drug Industry

The Saudi Arabian Diabetes Drug Market has regional divisions, including the Northern, Central, Southern, Eastern, and Western regions. About 37. 5% of the market share is held by the central region. The higher urban population and population density in the region are linked to higher rates of diabetes because of the sedentary lifestyles and eating habits. Moreover, central Saudi Arabia offers the greatest access to contemporary medical facilities and specialists. In this region, more proactive diabetes management and awareness campaigns can be found. Furthermore, urban centers like Riyadh have more per capita income, making it easier for citizens to get medication and other treatments including expensive ones like; insulin analogs and combination therapies.

Competitive Landscape

With strategic initiatives such as mergers, collaborations, and acquisitions, the leading market companies, including Novo Nordisk A/S, Takeda, Pfizer, Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, Merck and Co., AstraZeneca, Julphar, Bristol Myers Squibb, Novartis, Sanofi Aventis, and others are looking forward to strengthening their market positions.

Key Questions Answered in the Research Report                                  

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the country?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping up across the country?
6. How have buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2020-30?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?